BRIEF — Biomea Fusion Announces Phase 1 Results For Bmf — 650, Its Investigational Next — Generation Oral Small Molecule Glp — 1 Receptor Agonist

Oct 13 (Reuters) — Biomea Fusion, Inc.: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-generation Oral Small Molecule Glp-1 Receptor Agonist Biomea Fusion - No Severe Or Serious Adverse Events Reported In Bmf-650 Phase 1 Mad Participants Biomea Fusion - All Adverse Events In Five Mad Cohorts Were Mild Or Moderate Biomea Fusion - No Increased Alt Or Ast Adverse Events Reported In Bmf-650 Phase 1 Study Biomea Fusion - Rapid One-step Titration To 400 Mg Qd Well Tolerated In Cohort 5 Biomea Fusion - Phase 1 Bmf-650 Shows 1.5%-3.2% Mean Weight Reduction At Day 29 In Cohorts 1-4 Biomea Fusion, Inc.: Mean Weight Reduction Ranged From 1.5% To 3.2% At Day 29 Across Cohorts 1-4, Compared With 0.1% For Pooled Placebo Biomea Fusion - Cohort 5 Shows 6.1% Mean Weight Reduction At Day 29, 1.55 Kg Per Week Biomea Fusion: In An Additional Fifth Cohort Conducted Under Confinement, At Day 29, Mean Weight Reduction Averaged About 1.55 Kg Per Week Biomea Fusion: Confinement Appears To Have Affected Eating Behavior For Cohort 5 Participants, Believe Its Results Should Be Interpreted Separately Source text:... Further company coverage: BMEA.O (Reuters.Briefs@thomsonreuters.